These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 12386826

  • 1. Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccines.
    Ribas A, Amarnani SN, Buga GM, Butterfield LH, Dissette VB, McBride WH, Glaspy JA, Ignarro LJ, Economou JS.
    Cancer Gene Ther; 2002 Nov; 9(11):875-83. PubMed ID: 12386826
    [Abstract] [Full Text] [Related]

  • 2. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [Abstract] [Full Text] [Related]

  • 3. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.
    Ribas A, Butterfield LH, Amarnani SN, Dissette VB, Kim D, Meng WS, Miranda GA, Wang HJ, McBride WH, Glaspy JA, Economou JS.
    Cancer Res; 2001 Dec 15; 61(24):8787-93. PubMed ID: 11751400
    [Abstract] [Full Text] [Related]

  • 4. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
    Xia DJ, Zhang WP, Zheng S, Wang J, Pan JP, Wang Q, Zhang LH, Hamada H, Cao X.
    Gene Ther; 2002 May 15; 9(9):592-601. PubMed ID: 11973635
    [Abstract] [Full Text] [Related]

  • 5. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.
    Wargo JA, Schumacher LY, Comin-Anduix B, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS, Ribas A.
    Cancer Gene Ther; 2005 Jun 15; 12(6):516-27. PubMed ID: 15775996
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J.
    J Immunother; 2006 Jun 15; 29(5):545-57. PubMed ID: 16971810
    [Abstract] [Full Text] [Related]

  • 10. Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10.
    Motomura Y, Senju S, Nakatsura T, Matsuyoshi H, Hirata S, Monji M, Komori H, Fukuma D, Baba H, Nishimura Y.
    Cancer Res; 2006 Feb 15; 66(4):2414-22. PubMed ID: 16489048
    [Abstract] [Full Text] [Related]

  • 11. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
    Tatsumi T, Takehara T, Kanto T, Miyagi T, Kuzushita N, Sugimoto Y, Jinushi M, Kasahara A, Sasaki Y, Hori M, Hayashi N.
    Cancer Res; 2001 Oct 15; 61(20):7563-7. PubMed ID: 11606395
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity.
    Tatsumi T, Takehara T, Yamaguchi S, Sasakawa A, Miyagi T, Jinushi M, Sakamori R, Kohga K, Uemura A, Ohkawa K, Storkus WJ, Hayashi N.
    Gene Ther; 2007 Jun 15; 14(11):863-71. PubMed ID: 17344900
    [Abstract] [Full Text] [Related]

  • 14. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D, Zheng S, Zhang W, He L, Wang Q, Pan J, Zhang L, Wang J, Cao X.
    J Mol Med (Berl); 2003 Sep 15; 81(9):585-96. PubMed ID: 12937899
    [Abstract] [Full Text] [Related]

  • 15. Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2.
    Shimizu K, Fields RC, Redman BG, Giedlin M, Mulé JJ.
    Cancer J Sci Am; 2000 Feb 15; 6 Suppl 1():S67-75. PubMed ID: 10685663
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic properties of DNA-based fibroblast and dendritic cell vaccines in mice with squamous carcinoma.
    O-Sullivan I, Kim TS, Chopra A, Cohen EP.
    Anticancer Res; 2006 Feb 15; 26(2A):873-84. PubMed ID: 16619482
    [Abstract] [Full Text] [Related]

  • 17. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma.
    Knippertz I, Hesse A, Schunder T, Kämpgen E, Brenner MK, Schuler G, Steinkasserer A, Nettelbeck DM.
    J Immunother; 2009 Jun 15; 32(5):524-38. PubMed ID: 19609245
    [Abstract] [Full Text] [Related]

  • 18. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity.
    Saha A, Chatterjee SK, Foon KA, Primus FJ, Bhattacharya-Chatterjee M.
    Cancer Res; 2003 Jun 01; 63(11):2844-54. PubMed ID: 12782590
    [Abstract] [Full Text] [Related]

  • 19. Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines.
    Akiyama Y, Watanabe M, Maruyama K, Ruscetti FW, Wiltrout RH, Yamaguchi K.
    Gene Ther; 2000 Dec 01; 7(24):2113-21. PubMed ID: 11223993
    [Abstract] [Full Text] [Related]

  • 20. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y, Saxena A, Zheng C, Carlsen S, Xiang J.
    J Gene Med; 2004 Aug 01; 6(8):857-68. PubMed ID: 15293344
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.